闭环支架优势.-in service

1BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.ConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.闭环设计优势CarotidWallstent®andFilterWire®EZSystem2BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.不同支架设计•开环设计•闭环设计CarotidWallstentTMPreciseTMAcculinkTM3BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.ConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.闭环单元设计4BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.闭环单元设计的三大要素RadialForceScaffoldingCellDesign主要目的：通过临床数据的支持整合闭环设计的三大组成以将CarotidWallstent区分于其他颈动脉支架StentLumen径向支撑力支架网孔面积单元结构设计5BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.ConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.支架网孔面积如何影响临床结果?6BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.CAS的目的CAS的目的是预防卒中的再次发生卒中是第三大死因，且是致残的首要因素.*DataonfileatBSC.7BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.颈动脉支架的植入…防止斑块的脱落是首要目的！斑块覆盖是最重要的！8BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.支架网孔面积不同的支架不同…CWS的网孔面积只有Acculink的1/109BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.闭环单元设计优势Benefit#1–支架网孔面积10BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.DoesCarotidStentDesignInfluenceOutcomes?R.M.Bersin,CatheterizationandCardiovascularInterventions2008;72:863–866目前为止，已经完成3项有关颈动脉支架设计与临床结果的回顾性、非随机研究。1.DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.Aretrospectiveanalysisof30dayoutcomesofacarotidarterystentingmulticenterdatabaseconsistingof3179consecutivepatients2.SPACE,aretrospective,randomizedtrialofcarotidarterystentingversusendarterectomyinstandardsurgicalriskpatientswithsymptomaticcarotidarterystenoses3.SchillingerM,GschwendtnerM,ReimersB,etal.Doescarotidstentcelldesignmatter?Aretrospective,nonrandomizedreviewofacarotidarterystentingmulticenterdatabaseconsistingof1,684consecutivepatientsDoesCarotidStentDesignInfluenceOutcomes?Bersin.CatheterizationandCardiovascularInterventions2008;72:863–866..11BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.•目的:明确颈动脉支架设计，尤其是支架网孔面积，对于颈动脉支架术后30天卒中、死亡或TIA的影响。•30天结果的回顾性分析–TIA，死亡,大和小卒中(非心肌梗死)•共3179接受颈动脉支架手术的患者•4个中心–Bosiers,Deloose-Belgium–Peeters,Verbis-Belgium–Setacci,Donatoetal.-Italy–Cremonesi,Castriota-ItalyDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.12BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.•闭环支架定义为支架网孔面积5.0mm2–例如•CarotidWALLSTENT®Endoprosthesis•XACT®CarotidStent•开环支架定义为支架网孔面积5.0mm2–例如–Precise®RxNitinolStentSystem–RXAcculink®CarotidStentDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.PreciseisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.13BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinformationofBostonScientificCorporation.Donotcopyordistribute.第30天事件：闭环vs.开环支架设计TIA,死亡,大和小卒中2.3%2.3%2.2%4.2%2.2%7.0%0%1%2%3%4%5%6%7%SymptomaticAsymptomaticTotalPopulationClosedCell(5mm2)OpenCell(5mm2)DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.对于症状性患者，术后第30天的主要事件发生率差异显著开环支架设计(7.0%)VS闭环支架设计(2.2%)(p0.0001)DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.N=3179P=0.005N=1317P0.0001N=1862P=1.014BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyConfidentialinf